• Molecular NameCefotaxime
  • SynonymCefotaximeCefotaxime sodium; Cephotaxime
  • Weight455.472
  • Drugbank_IDDB00493
  • ACS_NO63527-52-6
  • Show 3D model
  • LogP (experiment)-0.685
  • LogP (predicted, AB/LogP v2.0)-0.13
  • pkaN/A
  • LogD (pH=7, predicted)-4.15
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-0.94
  • LogSw (predicted, AB/LogsW2.0)2.45
  • Sw (mg/ml) (predicted, ACD/Labs)0.12
  • No.of HBond Donors4
  • No.of HBond Acceptors12
  • No.of Rotatable Bonds8
  • TPSA227.05
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy.
  • Absorption_value0.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding36.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life0.8~1.4 h
  • Excretion50~85% renal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAdverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions.
  • LD50 (rat)Oral rat LD50 is over 20,000 mg/kg while intravenous rat LD50 is over 7,000 mg/kg.
  • LD50 (mouse)N/A